Previous Guests

John Rubino
Cherie Leeden

Click here to listen to previous episodes.

About Chen Lin

Author "What is Chen Buying? What is Chen Selling?" Chen grew $5,400 to $2.3 million in 10 years. Learn More

Bristol-Myers Slashes Outlook As Q4 Profit Misses The Mark

From Bristol-Myers Squibb Co (NYSE:BMY) early Thursday posted mixed fourth quarter earnins reuslts and lowered its 2017 outlook, amid fears of regulators capping drug prices.

The New York City-based pharmaceuticals giant reported Q4 EPS of $0.63, which was $0.03 worse than the Wall Street consensus estimate of $0.66. Revenues surged 22.3% from last year to $5.24 billion, however, beating analysts’ $5.13 billion view. BMY also noted that international revenues increased an even better 25%, or 28% when excluding currency exchange effects.

Bristol-Myers’ gross margin as a percentage of revenue fell to 73.6% in the latest period, down from 77.8%, hurt by an unfavorable product mix.

BMY provided the following global revenue results for its drugs in Q4:

  • Opdivo grew by $835 million
  • Eliquis grew by $346 million (up 57%)
  • Orencia grew 16%
  • Sprycel grew 15%
  • Yervoy had sales of $264 million

Looking ahead, BMY cut its earnings guidance for 2017. It now expects EPS for the year of $2.70 to $2.90, which is lower than Wall Street’s $2.97 estimate. Worldwide revenues are now seen rising in the low-single digits (previously, BMY expected a high-teens increase), and gross margin as a percentage of revenue is now expected to range from 72% to 73% (down from a prior 75%).

Bristol-Myers Squibb Co shares fell $1.05 (-2.12%) in premarket trading Thursday. Prior to today’s report, BMY had declined -14.65% year-to-date, versus a 2.70% rise in the benchmark S&P 500 index during the same period.

BMY currently has a POWR Rating of D (Sell), and is ranked #53 of 133 stocks in the Medical – Pharmaceuticals category.

This article is brought to you courtesy of

You are viewing an abbreviated republication of ETF Daily News content. You can find full ETF Daily News articles on (

Powered by WPeMatico

Current Guests

Scott Berdahl

Click here for more details on guests.